Factors Affecting Compliance to Anti-Vascular Endothelial Growth Factor Treatment of Diabetic Macular Edema in a Cohort of Jordanian Patients.

Nakhleh E Abu-YaghiAlaa M AbedDana F KhlaifatMohammed Bassam NawaisehLaith O EmoushHeba Z AlHajjajAla M AbojaradehMariana N HattarSura K AbusaleemHashem M SabbaghYazan A Abu GharbiehSura A Quaqazeh

Published in: Clinical ophthalmology (Auckland, N.Z.) (2020)

VEGF suppression via the intravitreal route to treat DME is a long-term process that requires caregiver dedication but also proper patient compliance. Addressing real-life barriers in those patients may help guide future strategies to improve the treatment experience, lower the financial burden and contribute to better outcomes. Patients' perceptions of possible treatment outcomes at the short term may influence their long-term commitment to therapy.

Keyphrases

vascular endothelial growth factor
end stage renal disease
ejection fraction
chronic kidney disease
stem cells
type diabetes
primary care
endothelial cells
metabolic syndrome
skeletal muscle
bone marrow
mesenchymal stem cells
risk factors
combination therapy